Figure 6.

ANCA and anti-hLAMP-2 antibody titers in patients with AAV. (A and B) Sequential ANCA titers expressed as median and interquartile range in the 43 patients in the Groningen cohort followed for 12 months. ANCA titers decreased rapidly after the induction of treatment. The patients are separated into those who had PR3-ANCA (n=25; A and C) and MPO-ANCA (n=18; B and D). (C and D) Sequential titers of antibodies to hLAMP-2 measured by ELISA in the 43 patients in the Groningen cohort followed for 12 months. The upper limit of normal is 29 U and the yellow bar indicates the borderline positive. The patients are separated into those who had PR3-ANCA (n=25) and MPO-ANCA (n=18). Anti-hLAMP-2 antibodies became undetectable in <1 month in all but one of the patients. They became undetectable in all 37 positive patients, irrespective of the presence or absence of antibodies to either (C) PR3 or (D) MPO. (E) Sequential titers of antibodies to hLAMP-2 measured by ELISA in six patients from Groningen in the months preceding clinical relapse. The upper limit of normal is 29 U and the yellow bar indicates the borderline positive. Sera from four patients had detectable antibodies to hLAMP-2 before clinical relapse.